First Clinical Trial to Study Cannabis as Treatment for Migraine

Very excited about this announcement of the first randomized controlled clinical trial in the U.S. to investigate cannabis as a treatment option for migraine headaches. Clinically, I have seen numerous patients benefit from cannabinoid-based medicines when other migraine treatments have failed, so this is a huge step forward in advancing our understanding. 

Opinion: AU/NZ College of Anaesthetists Position Statement On the Use of Medicinal Cannabis

My opinion on the Australian and New Zealand College of Anaesthetists position statement on the use of medical cannabis for non-cancer chronic pain: Unbalanced, uninformed and hypocritical.

Last week, the Faculty of Pain Management at the Australian and New Zealand’s College of Anaesthetists (ANZCA) published guidance for health practitioners recommending against the prescription of medicinal cannabis for the treatment of chronic non-cancer pain (CNCP). We’ve seen a number of similar reviews over the last few years in both Australia and Canada and they continue to follow the same playbook. I weigh-in on the latest one in this video. I also encourage you to check out the balanced and very well-researched analysis written by Rhys Cohen here: https://www.cannabiz.com.au/medicinal-cannabis-and-chronic-pain-absence-of-evidence-is-not-evidence-of-absence/

Remember: “Absence of evidence is not evidence of absence.”

CBD Reduces Plaque, Improves Cognitive Function in Model of Familial Alzheimer's

There is a dire need for novel therapies to improve outcomes for patients with Alzheimer’s Disease, which is considered one of the fastest-growing health threats of our time. 

In a promising new study published in the Journal of Alzheimer’s Disease, investigators reported that a two-week course of high dose CBD helped reduce plaque and improve cognitive function in an experimental model of early onset familial AD.

Familial disease is an inherited version of Alzheimer’s in which symptoms typically surface in the 30s and 40s and occurs in about 10-15% of patients.

Next steps include determining optimal doses and giving CBD earlier in the disease process. They also are exploring delivery systems including the use of an inhaler that should help deliver the CBD more directly to the brain. 

See article below for more information. https://www.sciencedaily.com/releases/2021/03/210309192548.htm 

Citation for journal article, available here https://pubmed.ncbi.nlm.nih.gov/33612548/

Medical Cannabis and Cognitive Performance in Middle to Old Adults Treated For Chronic Pain

A new study assessing the relationship between long term medical cannabis use and cognitive function amongst middle-aged and older chronic pain patients has shown no association with declines in cognitive performance. 

Researchers assessed psychomotor reaction, attention, working memory and new learning. Dosage, concentrations, length of time using medical cannabis and frequency of use were also assessed. 

These results are extremely encouraging and should support patients and practitioners alike in their risk-benefit analysis when determining whether medical cannabis is a suitable treatment option.

Read the full research paper here.